CDH16 and oncocytic adenoma: CDH16 positivity was particularly frequent in nephrogenic adenomas (100%), oncocytomas (98%), chromophobe (97%), clear cell (85%), and papillary (76%) renal cell carcinomas (RCCs), follicular adenomas (86%) and follicular carcinomas (60%) of the thyroid, clear cell (56%), mucinous (36%), and endometroid (16%) carcinoma and carcinosarcoma (18%), of the ovary, adenocarcinoma of the cervix uteri (40%), serous (33%), clear cell (33%), and endometroid carcinoma (18%) of the endometrium as well as in various subtypes of neuroendocrine neoplasms (4–26%).